CVKD: שווי חברה לרווח נקי Cadrenal Therapeutics, Inc

סמל תאגידי ולוגו של Cadrenal Therapeutics, Inc (CVKD)

Cadrenal Therapeutics (CVKD) develops safe anticoagulants for individuals with renal pathologies. This historical price chart illustrates the dynamics of the company, which has a P/E ratio of -0.50. The business relies on the monetization of patent protection, ensuring the steady sale of life-saving medications. Simultaneously, the biopharmaceutical startup is advancing its own research, seeking strategic partners to bring new developments to market without merging with corporate behemoths.

Cadrenal Therapeutics, Inc. (CVKD): מכפיל P/E מ-28.04.2023 עד 16.11.2026

פילוחים אנליטיים של חברת Cadrenal Therapeutics

- מחיר ותחזית קונצנזוס למחירים:
ניתוח מסכם של החברה:CVKD (Cadrenal Therapeutics, Inc)
דוגמת מוצר של cadrenal.com

To isolate fundamental stability from market noise, capital utilizes the ratio of market capitalization to actual income to measure the investment payback period. By analyzing the P/E ratio based on net profit, an investor assesses the fair value of Cadrenal Therapeutics (CVKD), whose strong pricing power and patents for Tecarfarin ensure stable demand from dialysis patients.